Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... . Results. In patients with relapsed or refractory CD30-positive HL after ASCT ICER was 5,8 million rub. per ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... radio iodine refractory differentiated thyroid cancer in the Russian Federation. Methods. Cost ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory ..."
 
Vol 10, No 2 (2017) ФАРМАКОЭКОНОМИЧЕСКАЯ ОЦЕНКА ПРИМЕНЕНИЯ ПОМАЛИДОМИДА (ИМНОВИД) ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С РЕЦИДИВИРУЮЩЕЙ И РЕФРАКТЕРНОЙ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ Abstract  similar documents
,
"... обеспечения доступности препарата за счет средств бюджетов здравоохранения пациентам с рецидивирующей и ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... antibiotic in the therapy of acute obstructive bronchitis,. The highest value ICER ratio was obtained ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... are treated for refractory POS & PGTCS each year. The market share of perampanel in the perampanel adoption ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... показателей препарата окрелизумаб (Окревус®) в терапии рецидивирующих форм рассеянного склероза (РРС) у ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... , QALY, ICER, «cost-utility» analysis, liraglutide, glimepiride, metformin. 18. McGill J.B. Insights ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
 
Vol 7, No 3 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA Abstract  similar documents
A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova
"... .1%. ICER for eloxatin was 8,801 and 18,162 compared to eksorum and platikad respectively. As a result ..."
 
Vol 12, No 2 (2019) New framework for the development of clinical guidelines in Russia Abstract  similar documents
D. V. Blinov, E. S. Akarachkova, A. S. Orlova, E. V. Kryukov, D. I. Korabelnikov
"... качество оказания медицинской помощи, оказать позитивное влияние на медицинское страхование и судебные ..."
 
Vol 9, No 3 (2016) МЕТОД «ЗАТРАТЫ – ЭФФЕКТИВНОСТЬ» В ОЦЕНКЕ АНТИБИОТИКОТЕРАПИИ ОСТРОГО ОБСТРУКТИВНОГО БРОНХИТА У ДЕТЕЙ В УСЛОВИЯХ СТАЦИОНАРА Abstract  similar documents
,
"... – макролидов при терапии острого обструктивного бронхита.  Наибольшее значение коэффициента ICER было получено ..."
 
Vol 7, No 2 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
"... рецидивирующем тече- нии множественной миеломы и других злокачественных плазмо- клеточных новообразований ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... литературы, отобранных для систематиче- ского обзора, авторы отмечали неизменные позитивные адъю- вантные ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... as it had clinical benefits with affordable additional expenses. The increment cost efficiency rate (ICER ..."
 
Vol 8, No 2 (2015) MAGNESIUM DEFICIENCY OF PATIENTS WITH HORMONE DEPENDENT DISEASES: PHARMACOEPIDEMIOLOGICAL PROFILE AND LIFE QUALITY ASSESSMENT Abstract  similar documents
Dmitry Vladislavovich Blinov, Juliana Vladimirovna Zimovina, Elena Anatol'evna Sandakova, Tat'yana Igorevna Ushakova
"... улучшает состояние пациентов, также как и позитивно влияет на показатели качества жизни. ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... on the ICER analysis, the additional expenses associated with a wider use of preventive therapy in scenarios 1 ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... -эффективность» рассчитан по формуле , где: ICER – инкрементальный коэффициент «затраты- эффективность»; Cost ..."
 
Vol 9, No 4 (2016) PROPOSALS AND RECOMMENDATIONS FOR OPTIMIZATION OF THE PROGRAM OF STATE GUARANTEES FОR FREE MEDICAL CARE FOR RUSSIAN CITIZENS Abstract  similar documents
D. V. Fedyaev, D. V. Lukyantseva, V. I. Ignatyeva
"... услуг) и использование различных сценариев (негативный, позитивный и др.). Помимо самих гарантий ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer ..."
 
Vol 5, No 2 (2012) PHARMACOEPIDEMIOLOGY OF PHYSICIANS’ INDICATIONS IN PATIENTS WITH POSTINFARCTIONCARDIOSCLEROSIS Abstract  similar documents
O. N. Kurochkinа, A. L. Khokhlov, N. M. Boyankova
"... доказанным позитивным влиянием на прогноз: рамиприл и периндоприл (рекомендации – 55,1%, амбулаторные ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... другим был про- веден инкрементальный анализ (incremental cost-effectiveness ratios – ICERs). ICER=(ПЗ 1 ..."
 
Vol 7, No 1 (2014) CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS Abstract  similar documents
I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok
"... эффективности затрат» (ICER) по- зволяет оценить стоимость одной дополнительной единицы эф- фективности при ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... рефрактерных форм лимфопролиферативных и миелопролиферативных заболе- ваний, в т.ч. у детей. Комплексная ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Dexamethasone for relapsed or refractory multiple myeloma. N engl J med. 2007;357(21):2123-32. 4. greipp pr ..."
 
Vol 8, No 4 (2015) APPROACHES TO THE CONCEPTS OF PRODUCTIVITY, EFFICIENCY AND EFFECTIVENESS IN THE FIELD OF SCIENTIFIC RESEARCH AND DEVELOPMENT Abstract  similar documents
O. F. Seliverstova
"... т.п.). Конечные результаты – ожидаемые позитивные последствия по- лученных непосредственных ..."
 
Vol 6, No 4 (2013) Using indirect comparisons in pharmacoeconomic examination Abstract  similar documents
Yu. E. Balykina, A. S. Kolbin
"... ) и инкрементального коэффициента ICER (incremental cost- effectiveness ratio) [20]. Другим примером ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... - дился расчет инкрементального коэффициента ICER, указываю- щего на количество дополнительных денежных ..."
 
Vol 7, No 2 (2014) CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM Abstract  similar documents
I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek
"... приращения затрат (ICER, ICUR). Проведено определение целевой популяции пациентов, страда- ющих СтС и ..."
 
Vol 8, No 2 (2015) SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS Abstract  similar documents
Georgii Rubenovich Khachatryan, Vladislav Sergeevich Dombrovskii
"... заболевание сердечно-сосудистой системы (сердечная недостаточ- ность 4-й степени тяжести, рефрактерная ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2011; on line. 25. Garrett S ..."
 
Vol 5, No 1 (2012) MODERNIZATION OF THE MEDICAL SERVICES MARKET Abstract  similar documents
A. U. Kulikov
"... капитала и рост позитивных экстерналий наиболее ярко проявля- ется в первичном секторе здравоохранения, где ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... единицу полез- ности [9]. ICUR, аналогичный показателю ICER, который рассчитывается по формуле [2 ..."
 
Vol 7, No 4 (2014) ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva
"... счет цепочки посредников [2,4]. Несмотря на определенные позитивные изменения, связанные с введением ..."
 
Vol 6, No 2 (2013) VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» Abstract  similar documents
"... îöåíêè òåõíîëîãèé çäðàâîîõðàíåíèÿ (ÎÒÇ). Были отмечены позитивные тенденции в развитии ОТЗ: рост числа ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... полученных результатов, а также результатов ана- лиза затрат рассчитывается ICER для стратегии с более ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... - стика может быть выражена исключительно в виде инкременталь- ных коэффициентов – ICER (incremental cost ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... » рассчитывали по формуле , где ICER – инкрементальный коэффициент «затраты – эффек- тивность»; Cost1, Cost2 ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... хроническом Ph-позитивном миелолейкозе, рези- стентном к иматинибу. Современная онкология. 2010; 2: 6-9. 5 ..."
 
Vol 6, No 1 (2013) VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» Abstract  similar documents
"... pharmacoeconomic evaluation of drug supply for patients with metastatic hormone-refractory prostate cancer Когон ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... , которые служат противопоказа- нием для грудного вскармливания, или когда мать является ВИЧ- позитивной ..."
 
Vol 8, No 1 (2015) PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE Abstract  similar documents
D. V. Blinov, U. V. Zimovina, T. I. Ushakova
"... радномизированные, двойные-слепые исследования высокой степени доказательности, подтвердили их позитивное влияние ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... ,5 мес. соответственно; р<0,001) [10]. Но даже позитивная констатация значительного прогресса в борьбе ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... терапии (показатели на одного пациента). * Показатель ICER для стратегии с дапаглифлозином не ..."
 
1 - 47 of 47 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)